Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

Literature DB >> 19650678

Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

L La Colla¹, A Albertin, G La Colla.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Piperidines
Remifentanil

Year: 2009 PMID： 19650678 DOI： 10.2165/00003088-200948060-00005

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

3 in total

1. Caution when lean body weight is used as a size descriptor for obese subjects.

Authors: Bruce Green; Stephen Duffull
Journal: Clin Pharmacol Ther Date: 2002-12 Impact factor: 6.875

2. Quantification of lean bodyweight.

Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

3. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors: C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal: Anesthesiology Date: 1997-01 Impact factor: 7.892

3 in total

5 in total

1. Obesity and allometric scaling of pharmacokinetics.

Authors: Douglas J Eleveld; Johannes H Proost; Anthony R Absalom; Michel M R F Struys
Journal: Clin Pharmacokinet Date: 2011-11-01 Impact factor: 6.447

2. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

Authors: Luca La Colla; Andrea Albertin; Giorgio La Colla; Andrea Porta; Giorgio Aldegheri; Domenico Di Candia; Fausto Gigli
Journal: Clin Pharmacokinet Date: 2010 Impact factor: 6.447

Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

1. Caution when lean body weight is used as a size descriptor for obese subjects.

2. Quantification of lean bodyweight.

3. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

1. Obesity and allometric scaling of pharmacokinetics.

2. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

3. Optimum lean body formulation for correction of standardized uptake value in PET imaging.

4. Using Lean tools to improve the efficiency of awake fibreoptic intubation setup.

5. Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil.